Y-mabs Therapeutics Inc. Share Price (NASDAQ: YMAB)

Y-mabs Therapeutics Inc. Stock Performance

as on September 16, 2025 at 1:29 am IST

Day's Low
Day's High
$8.59
Day's Price Range
$8.61
$8.6
0.12%
Downside
0.12%
Upside
52 Week's Low
52 Week's High
$3.55
52-Week Price Range
$16.11
$8.6
58.72%
Downside
87.33%
Upside

Y-mabs Therapeutics Inc. share price movements today

Previous Close: $8.59
Open: $8.59
Volume: 803.7K
Day's Low - High: $8.59 - $8.61
52 Week Low - High: $3.55 - $16.11

Y-mabs Therapeutics Inc. Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Y-mabs Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Y-mabs Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

Y-mabs Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Y-mabs Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Y-mabs Therapeutics Inc.	BUY	$-	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.6B	230.86%	-505.15	-12.96%
Beone Medicines Ltd	NA	$35.8B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$104.6B	87.37%	29.01	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$61.1B	-5.1%	14.53	31.37%

Analyst Recommendation on Y-mabs Therapeutics Inc. Stock

Based on 13 analysts

BUY

76.92%

Buy

15.38%

Hold

7.69%

Sell

Based on 13 analysts, 76.92% of analysts recommend a 'BUY' rating for Y-mabs Therapeutics Inc.. Average target price of $8.6

Y-mabs Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Y-mabs Therapeutics Inc..

Target Price

$8.6

Current Price

$8.6

Analyzed by

13 Analysts

Target

$8.60

Y-mabs Therapeutics Inc. target price $8.6, a slight upside of 0% compared to current price of $8.6. According to 13 analysts rating.

Y-mabs Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	20	20	20	23	19	22	18	26	20	19
Gross Profit	18	16	17	21	17	19	16	18	17	16
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-5	-6	-7	0	-6	-9	-6	-6	-5	-3
Net Profit Margin	-25.17%	-30.37%	-37.88%	-4.23%	-33.26%	-40.57%	-37.91%	-25.63%	-24.86%	-16.59%

Y-mabs Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	20	34	65	84	87
Gross Profit	-	-	0	0	18	32	57	73	72
Operating Income	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	-17	-19	-43	-78	-119	-56	-96	-21	-29
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-575.12%	-161.46%	-147.59%	-25.26%	-33.83%

Global Institutional Holdings in Y-mabs Therapeutics Inc.

Funds	Holdings
Paradigm Biocapital Advisors LP	9.32%
BlackRock Inc	6.05%
Caligan Partners LP	5.16%
Sofinnova Ventures	4.83%
Vanguard Group Inc	4.28%

See all

Insights on Y-mabs Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 5 quarters, -9.24M → -3.23M (in $), with an average increase of 31.6% per quarter
POSITIVE IMPACT
Price Rise
In the last 3 months, YMAB stock has moved up by 79.4%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.2% return, outperforming this stock by 108.0%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 152.7%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 26.49M → 19.52M (in $), with an average decrease of 13.9% per quarter

About Y-mabs Therapeutics Inc.

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Organisation	Y-mabs Therapeutics Inc.
E-voting on shares	Click here to vote

FAQs

What is Y-mabs Therapeutics Inc. share price today?

Y-mabs Therapeutics Inc. share price today is $8.6 as on September 16, 2025 at 1:29 am IST at the close of the market. Y-mabs Therapeutics Inc. share today touched a day high of $8.61 and a low of $8.59.

What is the 52 week high and 52 week low for Y-mabs Therapeutics Inc. share?

Y-mabs Therapeutics Inc. share touched a 52 week high of $16.11 on November 7, 2024 and a 52 week low of $3.55 on May 15, 2025. Y-mabs Therapeutics Inc. stock price today i.e. September 16, 2025 at 1:29 am IST is closed at $8.6,which is 46.62% down from its 52 week high and 142.25% up from its 52 week low.

How to invest in Y-mabs Therapeutics Inc. Stock (YMAB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Y-mabs Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Y-mabs Therapeutics Inc. Shares that will get you 0.1744 shares as per Y-mabs Therapeutics Inc. share price of $8.6 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Y-mabs Therapeutics Inc. Stock (YMAB) from India?

Indian investors can start investing in Y-mabs Therapeutics Inc. (YMAB) shares with as little as ₹87.83 or $1 (as of October 17, 2025 at 3:02 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.30 in Y-mabs Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on October 17, 2025 at 3:02 pm IST). Based on Y-mabs Therapeutics Inc. share’s latest price of $8.6 as on September 16, 2025 at 1:29 am IST, you will get 1.1628 shares of Y-mabs Therapeutics Inc.. Learn more about fractional shares .